Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
27
ASBP Quote, Financials, Valuation and Earnings
Last price:
$0.97
Seasonality move
:
-14.54%
Day range:
$0.89 - $1.02
52-week range:
$0.55 - $35.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,805.36x
P/B ratio:
--
Volume:
164.6K
Avg. volume:
456.7K
1-year change:
-95.79%
Market cap:
$4.9M
Revenue:
$6.2K
EPS (TTM):
-$1.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
ACON
Aclarion, Inc.
|
$25K | -$1.55 | 31.58% | -83.37% | $7.00 |
|
ACRV
Acrivon Therapeutics, Inc.
|
$207.9K | -$0.52 | -- | -0.09% | $11.50 |
|
LUCY
Innovative Eyewear, Inc.
|
$700K | -$0.47 | 72.65% | -34.36% | $3.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$974K | -$0.81 | -8.03% | -97.28% | $146.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
$1.02 | -- | $4.9M | -- | $0.00 | 0% | 1,805.36x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ACON
Aclarion, Inc.
|
$3.57 | $7.00 | $3.9M | -- | $0.00 | 0% | 27.63x |
|
ACRV
Acrivon Therapeutics, Inc.
|
$1.52 | $11.50 | $61.3M | -- | $0.00 | 0% | -- |
|
LUCY
Innovative Eyewear, Inc.
|
$1.06 | $3.00 | $6.4M | -- | $0.00 | 0% | 1.52x |
|
PSTV
Plus Therapeutics, Inc.
|
$3.56 | $146.88 | $22.3M | -- | $0.00 | 0% | 3.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
-303.41% | 2.242 | 84.54% | 0.14x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ACON
Aclarion, Inc.
|
-- | 1.355 | -- | 14.42x |
|
ACRV
Acrivon Therapeutics, Inc.
|
2.35% | 1.519 | 3.55% | 7.57x |
|
LUCY
Innovative Eyewear, Inc.
|
0.31% | 3.244 | 0.53% | 6.38x |
|
PSTV
Plus Therapeutics, Inc.
|
17.04% | 1.919 | 1.16% | 1.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
$900 | -$1.1M | -2180.87% | -- | -60289.47% | -$1.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ACON
Aclarion, Inc.
|
-$59.5K | -$2M | -64.27% | -64.27% | -10772.97% | -$1.7M |
|
ACRV
Acrivon Therapeutics, Inc.
|
-$361K | -$20.1M | -52.82% | -54% | -- | -$15.5M |
|
LUCY
Innovative Eyewear, Inc.
|
$114.7K | -$2.5M | -79.95% | -80.45% | -260.4% | -$1.5M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$5.7M | -- | -- | -420.04% | -$6.3M |
Aspire Biopharma Holdings, Inc. vs. Competitors
-
Which has Higher Returns ASBP or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of 96.33%. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ASBP or ACAD?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is ASBP or ACAD More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock ASBP or ACAD?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or ACAD?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 1,805.36x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.1,805.36x -- $1.9K -$1.9M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns ASBP or ACON?
Aclarion, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of -10211.35%. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Aclarion, Inc.'s return on equity of -64.27%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M ACONAclarion, Inc.-321.62% -$2.21 $12.8M -
What do Analysts Say About ASBP or ACON?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aclarion, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 96.08%. Given that Aclarion, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Aclarion, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 ACONAclarion, Inc.1 0 0 -
Is ASBP or ACON More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aclarion, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ASBP or ACON?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aclarion, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Aclarion, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or ACON?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are smaller than Aclarion, Inc. quarterly revenues of $18.5K. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Aclarion, Inc.'s net income of -$1.9M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Aclarion, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 1,805.36x versus 27.63x for Aclarion, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.1,805.36x -- $1.9K -$1.9M ACONAclarion, Inc.27.63x -- $18.5K -$1.9M
-
Which has Higher Returns ASBP or ACRV?
Acrivon Therapeutics, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of --. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Acrivon Therapeutics, Inc.'s return on equity of -54%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M ACRVAcrivon Therapeutics, Inc.-- -$0.49 $115.2M -
What do Analysts Say About ASBP or ACRV?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Acrivon Therapeutics, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 656.58%. Given that Acrivon Therapeutics, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Acrivon Therapeutics, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 ACRVAcrivon Therapeutics, Inc.5 0 0 -
Is ASBP or ACRV More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Acrivon Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ASBP or ACRV?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acrivon Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Acrivon Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or ACRV?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are larger than Acrivon Therapeutics, Inc. quarterly revenues of --. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Acrivon Therapeutics, Inc.'s net income of -$19M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Acrivon Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 1,805.36x versus -- for Acrivon Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.1,805.36x -- $1.9K -$1.9M ACRVAcrivon Therapeutics, Inc.-- -- -- -$19M
-
Which has Higher Returns ASBP or LUCY?
Innovative Eyewear, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of -194.84%. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Innovative Eyewear, Inc.'s return on equity of -80.45%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M LUCYInnovative Eyewear, Inc.11.95% -$0.34 $9.1M -
What do Analysts Say About ASBP or LUCY?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Innovative Eyewear, Inc. has an analysts' consensus of $3.00 which suggests that it could grow by 183.02%. Given that Innovative Eyewear, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Innovative Eyewear, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 LUCYInnovative Eyewear, Inc.0 0 0 -
Is ASBP or LUCY More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innovative Eyewear, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ASBP or LUCY?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Innovative Eyewear, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or LUCY?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are smaller than Innovative Eyewear, Inc. quarterly revenues of $959.8K. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Innovative Eyewear, Inc.'s net income of -$1.9M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Innovative Eyewear, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 1,805.36x versus 1.52x for Innovative Eyewear, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.1,805.36x -- $1.9K -$1.9M LUCYInnovative Eyewear, Inc.1.52x -- $959.8K -$1.9M
-
Which has Higher Returns ASBP or PSTV?
Plus Therapeutics, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of -417.92%. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M PSTVPlus Therapeutics, Inc.93.27% -$0.04 $4.8M -
What do Analysts Say About ASBP or PSTV?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 PSTVPlus Therapeutics, Inc.3 1 0 -
Is ASBP or PSTV More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.
-
Which is a Better Dividend Stock ASBP or PSTV?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or PSTV?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 1,805.36x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.1,805.36x -- $1.9K -$1.9M PSTVPlus Therapeutics, Inc.3.21x -- $1.4M -$5.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
